EC Number |
Application |
Reference |
---|
2.5.1.58 | analysis |
procedure for labeling designed ankyrin repeat proteins (DARPins) engineered with a C-terminal CVIA sequence using an azide-containing FPP analog by yeast PFTase and procedures to subsequently conjugate the labeled DARPins to a TAMRA fluorophore |
759730 |
2.5.1.58 | drug development |
the enzyme from Aspergillus fumigatus is a target for antifungal drug design |
739602 |
2.5.1.58 | medicine |
- |
637511, 637514, 637515, 637516, 637517, 637525 |
2.5.1.58 | medicine |
analysis of reaction mechanism using catalytically active crystals and comparison with the human enzyme. In the CAAX binding site, a single residue substitution at the a2 site from tyrosine to asparagine results in a deeper cavity in this region compared with the human enzyme. The prenylated product exit groove is wider in the Cryptococcus neoformans enzyme relative to human enzyme and varies in amino acid composition. A substrate-induced conformational change observed for the 4alpha-5alpha loop of results in a molecular surface in the active site with two distinct states that can be individually exploited for inhibitor design |
-, 722725 |
2.5.1.58 | medicine |
design of a protein farnesyltransferase-driven plasma membrane-targeted chimeric peptide, PpIX-C6-PEG8-KKKKKKSKTKC-OMe, for plasma membrane-targeted photodynamic therapy and enhanced immunotherapy. The plasma membrane targeting ability of the peptide originates from the cellular K-Ras signaling, which occurs exclusively to drive the corresponding proteins to plasma membrane by protein farnesyltransferase |
758576 |
2.5.1.58 | medicine |
enzyme a target in developing drug therapy for malaria |
637524 |
2.5.1.58 | medicine |
enzyme from trypanosomatid parasites are target of anti-trypanosomatid agents because inhibitors of this enzyme are highly toxic to these parasites compared to mammalian cells |
-, 637511 |
2.5.1.58 | medicine |
evidence that inhibitors of enzyme could be effective therapeutic agents in treatment of many human cancers |
636537, 637501, 637502, 637503, 637505, 637507, 637512, 637513, 637523 |
2.5.1.58 | medicine |
farnesyltransferase inhibitors as potential cancer therapeutics |
705172 |
2.5.1.58 | medicine |
inhibition of protein farnesyltransferase with influence for oncogenesis, potential target for treatment of cancer |
705065 |